Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3882-3888

  Farrell, David J ^a,b   Flamm, Robert K ^a   Sader, Helio S ^a,c   Jones, Ronald N ^a,d  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; EUROPE; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; ISRAEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPECIES IDENTIFICATION; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TURKEY (REPUBLIC); BACTERIAL INFECTION; BACTERIUM; DRUG EFFECTS; HEALTH SURVEY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STANDARD; STANDARDS; TURKEY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; EUROPE; HUMANS; ISRAEL; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH SURVEILLANCE; REFERENCE STANDARDS; TURKEY;

EID: 84903130796     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02465-14     Document Type: Article

References (26)

1. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655. http://dx.doi.org/10. 1086/526527. (Pubitemid 351321545)
2. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44. http://dx.doi.org/10.1128/AAC.00551-07.
3. Nicholson SC, Welte T, File TM, Strauss RS, Michiels B. 2012. A randomized, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with our without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization. Int. J. Antimicrob. Agents 39:240-246. http://dx.doi.org/10.1016/j.ijantimicag.2011.11.005.
4. Noel GJ, Strauss R, Shah A, Bagchi P. 2008. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broadspectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836. http://dx.doi.org/10.1128/AAC.45.3. 825-836.2001. (Pubitemid 32182033)
6. Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. 2007. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:2621-2624. http://dx.doi.org/10. 1128/AAC.00029-07. (Pubitemid 47047351)
7. Bogdanovich T, Clark C, Ednie L, Lin G, Smith K, Shapiro S, Appelbaum PC. 2006. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50:2050-2057. http://dx.doi.org/10.1128/AAC.00044-06. (Pubitemid 43807525)
8. Arias CA, Singh KV, Panesso D, Murray BE. 2007. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51:2043-2047. http://dx.doi.org/10.1128/AAC.00131-07. (Pubitemid 46903092)
9. Leonard SN, Cheung CM, Rybak MJ. 2008. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2974-2976. http://dx.doi.org/10.1128/AAC.00257-08.
10. Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75. http://dx.doi.org/10.1016/j.diagmicrobio.2004.04.011. (Pubitemid 39360265)
11. Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. 2008. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn. Microbiol. Infect. Dis. 61:96-102. http://dx.doi.org/10.1016/j.diagmicrobio. 2008.02.013. (Pubitemid 351509756)
12. Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Lauffer JM, Lee E, Morrissey I, CLASS Study Group. 2011. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J. Antimicrob. Chemother. 66:151-159. http://dx.doi.org/10.1093/jac/dkq397.
13. Pillar CM, Aranza MK, Shah D, Sahm DF. 2008. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent grampositive and gram-negative isolates of European origin. J. Antimicrob. Chemother. 61:595-602. http://dx.doi.org/10.1093/jac/dkm492. (Pubitemid 351321133)
14. Jones RN, Masterton R. 2001. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41:171-175. http://dx.doi.org/10.1016/S0732-8893(01)00318-2. (Pubitemid 34056538)
15. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
17. EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters, version 3.1, February 2013. http://www.eucast.org/clinical- breakpoints/.
18. Zevtera. 2013. Summary of product characteristics. Basilea Medical Ltd., Basel, Switzerland.
19. Anderegg TR, Jones RN, Sader HS. 2004. Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. J. Clin. Microbiol. 42:3356-3358. http://dx.doi.org/10.1128/JCM.42.7.3356-3358.2004. (Pubitemid 38938114)
20. Torres A, Ferrer M, Badia JR. 2010. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin. Infect. Dis. 51(Suppl 1):S48-S53. http://dx.doi.org/10.1086/653049.
21. Barbier F, Andremont A, Wolff M, Bouadma L. 2013. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr. Opin. Pulm. Med. 19:216-228. http://dx.doi.org/10.1097/ MCP.0b013e32835f27be.
22. American Thoracic Society and Infectious Disease Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 15:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
23. Sligl WI, Marrie TJ. 2013. Severe community-acquired pneumonia. Crit. Care Clin. 29:563-601. http://dx.doi.org/10.1016/j.ccc.2013.03.009.
24. Blasi F, Mantero M, Santus P, Tarsia P. 2012. Understanding the burden of pneumococcal disease in adults. Clin. Microbiol. Infect. 18(Suppl 5):7-14. http://dx.doi.org/10.1111/j.1469-0691.2012.03937.x.
25. Jones RN, Sader HS, Moet GJ, Farrell DJ. 2010. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn. Microbiol. Infect. Dis. 68:334-336. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.024.
26. Wyeth Pharmeceuticals Inc. 2012. Tygacil package insert. Wyeth Pharmeceuticals Inc., New York, NY. www.tygacil.com.